By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Genomic Health, Inc. 

301 Penobscot Drive

Redwood City  California  94063  U.S.A.
Phone: 650-556-9300 Fax: 650-556-1132


SEARCH JOBS

About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 80 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.


Key Statistics


Email:
Ownership: Public

Web Site: Genomic Health, Inc.
Employees:
Symbol: GHDX
 




Segment
Biotechnology





Company News
Genomic Health, Inc. (GHDX) Presents Positive Proof-of-Concept Data for Bladder Cancer Liquid Biopsy Test 6/16/2015 9:33:44 AM
Genomic Health, Inc. (GHDX) To Present Proof-Of-Concept Bladder Cancer Liquid Biopsy Data At AACR Precision Medicine Meeting 6/11/2015 7:56:11 AM
ASCO15: Oncotype DX Presentations At ASCO In Breast And Prostate Cancer Reinforce Genomic Health, Inc. (GHDX)'s Leadership In Optimizing Cancer Treatment 6/1/2015 7:38:57 AM
Multiple Oncotype DX Presentations At The ASCO Annual Meeting Highlight Genomic Health, Inc. (GHDX)'s Leadership In Personalizing Breast, Prostate Cancer Care 5/27/2015 10:01:26 AM
Genomic Health, Inc. (GHDX) To Present At The Jefferies and Co. 2015 Global Healthcare Conference 5/27/2015 9:48:45 AM
Genomic Health, Inc. (GHDX) Announces Favorable Draft Local Coverage Determination From Palmetto GBA On Medicare Coverage For The Oncotype DX Prostate Cancer Test 5/21/2015 6:49:48 AM
Genomic Health, Inc. (GHDX) Advances Liquid Biopsy Pipeline, Shows Ability To Accurately Monitor Urine For Presence Of Bladder Cancer 5/18/2015 6:53:56 AM
Genomic Health, Inc. (GHDX) Release: Oncotype DX Prostate Cancer Test Improves Risk Assessment For One In Four Men And Reduces Overall Healthcare Costs 5/15/2015 6:43:43 AM
Genomic Health, Inc. (GHDX) To Present Multiple Oncotype DX Studies And Positive Liquid Biopsy Results At American Urological Association Annual Meeting May 15-19 5/7/2015 12:20:37 PM
Genomic Health, Inc. (GHDX) To Present At The Bank of America (BAC) Merrill Lynch 2015 Healthcare Conference 5/6/2015 11:19:54 AM
12345678910...
//-->